CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Trading 04-16 11:54:02 EDT

8.79

+0.14

+1.62%

High8.85	Low8.35	Vol97.77K
Open8.66	D1 Closing8.65	Amplitude5.78%
Mkt Cap419.88M	Tradable Cap268.97M	Total Shares47.77M
T/O850.50K	T/O Rate0.32%	Tradable Shares30.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":8.79,"timestamp":1776354815763,"preClose":8.65,"halted":0,"volume":97771,"delay":0,"changeRate":0.016184971098265756,"floatShares":30599941,"shares":47768000,"eps":-0.897422,"marketStatus":"Trading","change":0.14,"latestTime":"04-16 11:54:02 EDT","open":8.66,"high":8.85,"low":8.35,"amount":850497.120999,"amplitude":0.057803,"askPrice":8.83,"askSize":302,"bidPrice":8.79,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-0.897422,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":8.65,"preHourTrading":{"tag":"盘前","latestPrice":8.68,"preClose":8.65,"latestTime":"09:29 EDT","volume":102,"amount":885.8000280000001,"timestamp":1776346199999,"change":0.03,"changeRate":0.003468,"amplitude":0.025434},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"17:38 EDT","volume":11302,"amount":97760.94,"timestamp":1776289094539,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.423941,"impliedVol":0.5198,"impliedVolPercentile":0.0508},"requestUrl":"/m/hq/s/CLYM/","defaultTab":"news","newsList":[{"id":"2627889404","title":"Climb Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2627889404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627889404?lang=en_us&edition=fundamental","pubTime":"2026-04-15 16:05","pubTimestamp":1776240334,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y03L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626411028","title":"Climb Bio announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626411028","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626411028?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:07","pubTimestamp":1775851646,"startTime":"0","endTime":"0","summary":"Climb Bio schedules 2026 annual stockholder meeting for June 5, 2026, to be held virtually via Internet.Meeting agenda includes election of two Class II directors: Alexander  Cumbo, Douglas Williams.Ballot includes amendment to certificate of incorporation covering removal of directors for cause.Vote also set on amendment to 2021 equity incentive plan to include prefunded warrants in annual automatic share pool increase calculation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL1BM3xN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626194162","title":"Climb Bio (CLYM) Gets a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2626194162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626194162?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:17","pubTimestamp":1775819860,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Climb Bio today and set a price target of $23.00. According to TipRanks, Rahimi is ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/climb-bio-clym-gets-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/climb-bio-clym-gets-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625044948","title":"Climb Bio hosts R&D Spotlight webcast on budoprutug CD19 program opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2625044948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625044948?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:00","pubTimestamp":1775646049,"startTime":"0","endTime":"0","summary":"Climb Bio will host an R&D Spotlight webcast on budoprutug on May 5, 2026, at 8:00 a.m. ET.Session will outline development strategy for budoprutug, anti-CD19 antibody in trials for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus.David Jayne, University of Cambridge, will join management as guest speaker.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLy67DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","CLYM","BK4112","BK4585","SG9999014039.USD","LU0314104364.USD","SG9999014021.USD","SG9999014013.SGD","BK4139","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4539","SG9999014005.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912269","title":"Climb Bio Price Target Maintained With a $8.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912269","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625912269?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:49","pubTimestamp":1775641740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 05:49 ET (09:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932666","title":"Climb Bio says FDA grants Fast Track designation for budoprutug in pMN","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932666","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932666?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:04","pubTimestamp":1775559884,"startTime":"0","endTime":"0","summary":"Climb Bio received FDA Fast Track designation for budoprutug in primary membranous nephropathy.Decision supports accelerated development pathway for investigational anti-CD19 antibody in rare kidney disease with no FDA-approved treatments.Phase 2 open-label PrisMN trial remains enrolling, with initial data expected in H2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL7jRVM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932849","title":"Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932849?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA5RVNJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625323039","title":"Climb Bio Inc - to Share Initial Phase 2 Data in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625323039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625323039?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA5RVNJ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664686","title":"Climb Bio Inc - Susan Altschuller to Serve as Principal Accounting Officer Effective April 30, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664686","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664686?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:26","pubTimestamp":1775247964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40M00K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664852","title":"Climb Bio SVP Finance Cindy Driscoll to exit; CFO Altschuller adds accounting role","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664852","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664852?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:06","pubTimestamp":1775246806,"startTime":"0","endTime":"0","summary":"Climb Bio set separation of Senior Vice President, Finance Cindy Driscoll, effective April 30, 2026.Susan Altschuller will add principal accounting officer duties on April 30, 2026, alongside her CFO role.Altschuller joined Climb Bio as CFO in October 2025.She previously served as CFO of Cerevel Therapeutics until its acquisition by AbbVie in August 2024.Her earlier roles include CFO of ImmunoGen, former Alexion finance executive, and CFO of Dragonfly Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL6FtJBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1037948541.HKD","LU2112291526.USD","LU0098860793.USD","LU0912757837.SGD","LU0868494617.USD","LU1003077747.HKD","LU0122379950.USD","LU0942090050.USD","IE00BGHQF631.EUR","BK4585","LU2129689431.USD","SG9999001440.SGD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU2087621335.USD","LU2133065610.SGD","LU1023059063.AUD","IE00B2B36J28.USD","LU1732799900.SGD","IE0004445239.USD","LU1839511570.USD","LU1057294990.SGD","IE00BSNM7G36.USD","LU0965508806.USD","LU0511384066.AUD","BK4139","LU0158827948.USD","SG9999015986.USD","CLYM","LU1989772840.SGD","LU2129689514.USD","LU0198837287.USD","LU2089283258.USD","IE00BLSP4452.SGD","LU1929549753.HKD","ABBV","IE00B4R5TH58.HKD","BK4581","IE00B19Z3B42.SGD","LU0689472784.USD","LU0943347566.SGD","LU0795875169.SGD","LU1983299246.USD","LU2237443895.HKD","LU1162221912.USD","LU1244550577.SGD","SG9999011175.SGD","LU0203347892.USD","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621605600","title":"Climb Bio Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2621605600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621605600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:13","pubTimestamp":1774357980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 09:13 ET (13:13 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232592","title":"Climb Bio Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232592?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:34","pubTimestamp":1773830040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 06:34 ET (10:34 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHX","FDS","BTGO","CCL","XYZG","BKKT","CTMX","CALM","DOW","GLXY","ETR","BTSG","COHR","CLYM","CE","EQIX","STZ","DC","GLXU","HQY","DUOL","IE00BMG7P926.USD","CRC","ARCT","BL","GEMI","CF","LU2360107671.USD","ANDG","GLGG","ANRO","GEMG","XYZY","CLH","AJG","DOCU","ALDX","ECL","ASO","EVMN","FICO","APD","GHM","CADL","DTE","XYZ","LU1923621640.USD","DLR","APGE","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618941694","title":"Climb Bio Inc : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941694?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:29","pubTimestamp":1773228591,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618916466","title":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2618916466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618916466?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:10","pubTimestamp":1773213002,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, OracleMarch 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, includin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"73f0b19cff544fe0a24216c0d940c1eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKNU","ADC","ORCS","AVR","BMRN","SJM","ELV","HIMY","MET","CHH","ORCU","ABM","CNC","HWM","HIYY","REGN","AVXX","HIMZ","DXCM","HAE","NKE","BLND","HIMS","HAS","PGNY","CRBG","ALMS","ORCL","FICO","EXPE","CLYM","CDW","APYX","HOG","H","UEC","BSX","DBI","CASY","EPRT","T","AVAV","RNA","BKNG","GEHC","HLT","CNCG","ABT","ORCX","HMYY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618937870","title":"Climb Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937870?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:40","pubTimestamp":1773142800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 07:40 ET (11:40 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618893914","title":"Climb Bio price target raised to $15 from $11 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618893914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618893914?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:15","pubTimestamp":1773137747,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $15 from $11 and keeps a Buy rating on the shares ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-15-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-15-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618826939","title":"Climb Bio, Inc. : H.c. Wainwright Raises Target Price to $15 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2618826939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618826939?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:11","pubTimestamp":1773137508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nAZN4SKHSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618984183","title":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618984183?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:23","pubTimestamp":1773127423,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx March 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","HIMZ","NXT","AMGN","MGNX","AAOI","CROX","LRCU","CCC","CASY","ADEA","DOW","FIVE","CLYM","HPE","FCEL","MAZE","CRWD","HIYY","ALEC","ARCB","HMYY","GILD","LU1941712264.USD","PSTG","FIGR","LRCX","FSS","KFY","IE00B7SZL793.SGD","IE00B19Z6F94.USD","ADBE","CELC","HCA","BETA","CRWL","GTLB","ADBG","BYRN","GO","CLRB","BIOA","HIMY","CHWY","HIMS","FDX","BBIO","TGT","DNTH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617907638","title":"Wedbush Raises Price Target on Climb Bio to $14 From $12, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617907638","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617907638?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:28","pubTimestamp":1772803720,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $12.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.2183},{"period":"1month","weight":0.2132},{"period":"3month","weight":1.2944},{"period":"6month","weight":3.4819},{"period":"1year","weight":5.3603},{"period":"ytd","weight":1.1625}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.090224},{"month":4,"riseRate":0.8,"avgChangeRate":0.281625},{"month":5,"riseRate":0.5,"avgChangeRate":0.027501},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.07628},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}